Evaluation and comparison of in vitro degradation kinetics of DNA in serum, urine and saliva: A qualitative study

Wang, Yao; Chen, Mei; Nan, Xuemei; Liu, Hui

doi:10.1016/j.gene.2016.06.033

Cited by 176 publications

(123 citation statements)

References 35 publications

Supporting

Mentioning

121

Contrasting

Unclassified

Order By: Relevance

“…These observations indicate that the administered chemotherapies were effective but not adequate. Due to the very short half‐life of cfDNA in plasma, monitoring ctDNA may be useful for the early detection of tumors anywhere in the body, and for the evaluation of the response to therapy …”

Section: Discussionmentioning

confidence: 99%

“…Small fragments of DNA derived from dead cells are ubiquitously present in circulating blood; they are known as cell‐free DNA (cfDNA). Despite their extremely short half‐life, cfDNA could provide vital clues regarding the disease state in many pathological conditions. The cfDNA derived from tumor cells is called circulating tumor DNA (ctDNA), and the amount of ctDNA in blood may correlate well with the tumor burden in the whole body, and also provide valuable information about the genetic variations observed in tumor cells .…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Early detection of the PAX3‐FOXO1 fusion gene in circulating tumor‐derived DNA in a case of alveolar rhabdomyosarcoma

Eguchi‐Ishimae

Tezuka

Kokeguchi

et al. 2019

Genes Chromosomes & Cancer

View full text Add to dashboard Cite

Cell‐free DNA (cfDNA), which are small DNA fragments in blood derived from dead cells including tumor cells, could serve as useful biomarkers and provide valuable genetic information about the tumors. cfDNA is now used for the genetic analysis of several types of cancers, as a surrogate for tumor biopsy, designated as “liquid biopsy.” Rhabdomyosarcoma (RMS), the most frequent soft tissue tumor in childhood, can arise in any part of the body, and radiological imaging is the only available method for estimating the tumor burden, because no useful specific biological markers are present in the blood. Because tumor volume is one of the determinants of treatment response and outcome, early detection at diagnosis as well as relapse is essential for improving the treatment outcome. A 15‐year‐old male patient was diagnosed with alveolar RMS of prostate origin with bone marrow invasion. The PAX3‐FOXO1 fusion was identified in the tumor cells in the bone marrow. After the diagnosis, cfDNA was serially collected to detect the PAX3‐FOXO1 fusion sequence as a tumor marker. cfDNA could be an appropriate source for detecting the fusion gene; assays using cfDNA have proved to be useful for the early detection of tumor progression/recurrence. Additionally, the fusion gene dosage estimated by quantitative polymerase chain reaction reflected the tumor volume during the course of the treatment. We suggest that for fusion gene‐positive RMSs, and other soft tissue tumors, the fusion sequence should be used for monitoring the tumor burden in the body to determine the diagnosis and treatment options for the patients.

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

Early detection of the PAX3‐FOXO1 fusion gene in circulating tumor‐derived DNA in a case of alveolar rhabdomyosarcoma

Eguchi‐Ishimae

Tezuka

Kokeguchi

et al. 2019

Genes Chromosomes & Cancer

View full text Add to dashboard Cite

show abstract

“…Release of cfDNA from cells after apoptosis and necrosis, lysis of cells in the bloodstream, and spontaneous release from cells under stress are possible sources of cfDNA. In people, DNA hydrolysis by DNAse 1 nuclease is the predominant pathway of cfDNA clearance from the blood, leading to a reported biological half‐life of 157.6 minutes at 37°C …”

mentioning

confidence: 99%

“…In people, DNA hydrolysis by DNAse 1 nuclease is the predominant pathway of cfDNA clearance from the blood, 5 leading to a reported biological half-life of 157.6 minutes at 37°C. 6 In 1948, the presence of cfDNA was reported in human serum. 7 Since then, increased concentrations of cfDNA in blood and body fluids have been linked to systemic lupus erythematosus 8 and various cancers.…”

mentioning

confidence: 99%

“…[15][16][17][18] Because of its short half-life, cfDNA is a reliable approximation of the current status of tissue injury and abates as resolution occurs. 6,15 In veterinary medicine, the focus of research on cfDNA has mainly centered on its potential value in the diagnosis, prognosis, and monitoring of the response to treatment of cancer in dogs. Dogs with mammary tumors or lymphoma have high concentrations of cfDNA in the blood, and the concentration of cfDNA is inversely correlated with remission time.…”

mentioning

confidence: 99%

See 1 more Smart Citation

Kinetics of Plasma Cell‐Free DNA and Creatine Kinase in a Canine Model of Tissue Injury

Wilson

Burchell

Worth

et al. 2017

Veterinary Internal Medicne

View full text Add to dashboard Cite

BackgroundCell‐free DNA (cfDNA) comprises short, double‐stranded circulating DNA sequences released from damaged cells. In people, cfDNA concentrations correlate well with disease severity and tissue damage. No reports are available regarding cfDNA kinetics in dogs.Objectives/HypothesisCell‐free DNA will have a short biological half‐life and would be able to stratify mild, moderate, and severe tissue injury. Our study aims were to determine the kinetics and biological half‐life of cfDNA and to contrast them with those of creatine kinase (CK).AnimalsThree groups of 10 dogs undergoing open ovariohysterectomy, surgery for cranial cruciate ligament rupture (CCLR), or hemilaminectomy.MethodsPlasma for cfDNA and CK analysis was collected at admission, at induction of anesthesia, postsurgery (time 0) and at 6, 12, 24, 36, 48, 60, and 72 hours after surgery.ResultsThe biological half‐life of plasma cfDNA and CK were 5.64 hours (95% confidence interval [CI 95], 4.36–7.98 hours) and 28.7 hours (CI95, 25.3–33.3 hours), respectively. In the hemilaminectomy group, cfDNA concentrations differed significantly from admission at 6–12 hours after surgery. Creatine kinase activity differed among the surgical groups and reached a peak 6 hours after surgery. In the ovariohysterectomy and CCLR groups, plasma CK activity 72 hours after surgery did not differ from admission activity of the ovariohysterectomy group. In contrast, in the hemilaminectomy group, plasma CK activity after 72 hours did not return to the ovariohysterectomy group admission activity.Conclusions and Clinical ImportancePlasma CK activity has a longer biological half‐life than previously thought. In contrast to plasma CK activity, cfDNA has a short half‐life and could be a useful marker for peracute severe tissue injury.

show abstract

Novel Polymer Systems for Gene Therapy

Diaz‐Dussan

Peng

Narain

2022

Macromolecular Engineering

View full text Add to dashboard Cite

Gene therapy is a novel molecularly directed gene‐editing technique that can be used in treating gene‐related diseases, and its clinical relevance relies on the design of effective therapeutic vectors that are able to deliver and release the nucleic acids to the targeted sites. The use of nanoscale vectors for gene delivery presents various advantages such as improved bioavailability, extended nucleotide half‐life, and reduced off‐target toxicity. Several types of colloidal systems have been developed, including biocompatible polymer carriers, such as nanoparticles, nanocapsules, and branched polymers. A first requisite is biocompatibility; reducing cell cytotoxicity and effective clearance from the organism is one of the major challenges, and particle size is also a key factor in the internalization process. Common cationic gene carriers are summarized here, but their associated cytotoxicity or low efficacy restricted their use at the clinical level. Numerous modifications for enhancing the vectors are introduced, which mainly involved the incorporation of biocompatible units and degradability. Furthermore, several methods in preparing nonviral carrier via controlled radical polymerization and their related postmodification techniques are summarized and discussed. Furthermore, the new generation of therapeutic nanoparticles, which combined selective targeting moieties, and imaging agents, offers a theranostic approach for enhanced gene therapy.

show abstract

Evaluation and comparison of in vitro degradation kinetics of DNA in serum, urine and saliva: A qualitative study

Cited by 176 publications

References 35 publications

Early detection of the PAX3‐FOXO1 fusion gene in circulating tumor‐derived DNA in a case of alveolar rhabdomyosarcoma

Early detection of the PAX3‐FOXO1 fusion gene in circulating tumor‐derived DNA in a case of alveolar rhabdomyosarcoma

Kinetics of Plasma Cell‐Free DNA and Creatine Kinase in a Canine Model of Tissue Injury

Novel Polymer Systems for Gene Therapy

Contact Info

Product

Resources

About